In this video, Joshua Brody, MD , discusses results from an ongoing phase 1a study of bexobrutideg, a novel Bruton’s tyrosine kinase degrader, for relapsed or refractory chronic lymphocytic leukemia.

Findings were presented at the Society of Hematologic Oncology’s Annual Meeting.

“The advent of degraders is huge in the entire space, and with some great successes, [there are] a lot of still pending questions,” Brody, director of the lymphoma immunotherapy program at The Tisch Cancer Institute at Mount Sinai, said. “Because BTK inhibition has been so powerful, so transformative for patients with CLL, the question is an obvious one: Would getting rid of the BTK molecule be better than just inhibiting it? That’s the question that’s being asked with this novel BTK degrader.”

In the stu

See Full Page